Potential role of renin-angiotensin system blockade for preventing myocardial ischemia/reperfusion injury and remodeling after myocardial infarction

Postgraduate Medicine

Volumn 123, Issue 2, 2011, Pages 49-55

  Dai, Wangde ^a   Kloner, Robert A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitor; Myocardial infarction; Renin inhibitor; Renin angiotensin system

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CANDESARTAN; CAPTOPRIL; CHYMASE; CHYMASE INHIBITOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; JANUS KINASE; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; OLMESARTAN; PLACEBO; POTASSIUM; QUINAPRIL; QUINAPRILAT; RAMIPRIL; RENIN; RENIN INHIBITOR; STAT PROTEIN; TRANDOLAPRIL; VALSARTAN;

ANGIONEUROTIC EDEMA; BOLUS INJECTION; COUGHING; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FIBRINOLYSIS; HEART DILATATION; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPOTENSION; LONG TERM CARE; NONHUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; REVIEW; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; RENIN; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR REMODELING;

EID: 79955090250     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.03.2263     Document Type: Review

References (43)

1. Przyklenk K, Kloner RA. "Cardioprotection" by ACE-inhibitors in acute myocardial ischemia and infarction? Basic Res Cardiol. 1993;88(suppl 1):139-154.
2. Kloner RA, Przyklenk K. Cardioprotection with angiotensin-converting enzyme inhibitors: redefined for the 1990s. Clin Cardiol. 1993;16(2):95-103.
3. Ertl G, Alexander RW, Kloner RA. Interactions between coronary occlusion and the renin-angiotensin system in the dog. Basic Res Cardiol. 1983;78(5):518-533.
4. Oyamada S, Bianchi C, Takai S, etal. Impact of acute myocardial ischemia reperfusion on the tissue and blood-borne renin-angiotensin system. Basic Res Cardiol. 2010;105(4):513-522.
5. Hirsch AT, Opsahl JA, Lunzer MM, Katz SA. Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction. Am J Physiol. 1999;276(6 pt 2):H1818-H1826.
6. Hirsch AT, Talsness CE, Schunkert H, etal. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991;69(2):475-482.
7. Busche S, Gallinat S, Bohle RM, etal. Expression of angiotensin AT(1) and AT(2) receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase-polymerase chain reaction study. Am J Pathol. 2000;157(2):605-611.
8. González GE, Seropian IM, Krieger ML, etal. Effect of early versus late AT(1) receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits. Am J Physiol Heart Circ Physiol. 2009;297(1):H375-H386.
9. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation. 1982;65(1):40-48.
10. Lazar HL, Bao Y, Rivers S, Bernard SA. Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury. Ann Thorac Surg. 2002;73(5):1522-1527.
11. Chen X, Minatoguchi S, Wang N, etal. Quinaprilat reduces myocardial infarct size involving nitric oxide production and mitochondrial KATP channel in rabbits. J Cardiovasc Pharmacol. 2003;41(6):938-945.
12. Dai W, Hale SL, Kay GL, etal. Cardioprotective effects of angiotensin II type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia-reperfusion model. Cardiovasc Ther. 2010;28(1):30-37.
13. Zhu B, Sun Y, Sievers RE, etal. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol. 2000;35(3):787-795.
14. Westermann D, Riad A, Lettau O, etal. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008;52(6):1068-1075.
15. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res. 1985;57(1):84-95.
16. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985;72(2):406-412.
17. Cavasin MA, Yang XP, Liu YH, etal. Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure. J Cardiovasc Pharmacol. 2000;36(4):472-480.
18. Guo X, Wang J, Elimban V, Dhalla NS. Both enalapril and losartan attenuate sarcolemmal Na+-K+-ATPase remodeling in failing rat heart due to myocardial infarction. Can J Physiol Pharmacol. 2008;86(4):139-147.
19. Miyazaki S, Kasai T, Miyauchi K, etal. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. Circ J. 2010;74(6):1158-1164.
20. Pfeffer MA, Braunwald E, Moyé LA, etal. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669-677.
21. Køber L, Torp-Pedersen C, Carlsen JE, etal. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333(25):1670-1676.
22. Flather MD, Yusuf S, Køber L, etal. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355(9215):1575-1581.
23. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-1675.
24. Pfeffer MA, Swedberg K, Granger CB, etal; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759-766.
25. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360(9335):752-760.
26. Pfeffer MA, McMurray JJ, Velazquez EJ, etal; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-1906.
27. Sharma JN, Al-Sherif GJ. Pharmacologic targets and prototype therapeutics in the kallikrein-kinin system: bradykinin receptor agonists or antagonists. Scientific World Journal. 2006;6:1247-1261.
28. Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther. 2006;112(3):668-676.
29. Jalowy A, Schulz R, Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. J Am Soc Nephrol. 1999;10(suppl 11):S129-S136.
30. Lemarié CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2010;11(1):19-31.
31. Sandmann S, Li J, Fritzenkötter C, etal. Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats. Blood Press. 2006;15(2):116-128.
32. Wang LX, Ideishi M, Yahiro E, etal. Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury. Hypertens Res. 2001;24(2):179-187.
33. Kossmehl P, Kurth E, Faramarzi S, etal. Mechanisms of apoptosis after ischemia and reperfusion: role of the renin-angiotensin system. Apoptosis. 2006;11(3):347-358.
34. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161-1172.
35. Milliez P, Messaoudi S, Nehme J, etal. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol. 2009;296(2):H435-H441.
36. Ocaranza MP, Lavandero S, Jalil JE, etal. Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens. 2010;28(5):1054-1064.
37. Jain M, Liao R, Ngoy S, etal. Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodelling in rats. Cardiovasc Res. 2000;46(1):66-72.
38. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292(1):C82-C97.
39. Mascareno E, El-Shafei M, Maulik N, etal. JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation. 2001;104(3):325-329.
40. El-Adawi H, Deng L, Tramontano A, etal. The functional role of the JAK-STAT pathway in post-infarction remodeling. Cardiovasc Res. 2003;57(1):129-138.
41. Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol. 2006;291(4):H1738-H1745.
42. Kassiri Z, Zhong J, Guo D, etal. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. 2009;2(5):446-455.
43. Xu J, Carretero OA, Lin CX, etal. Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2007;293(3):H1900-H1907.